At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 495 enrolled
Drug / intervention
Anamorelin HCl +1 moredrug
Likely dose
Anamorelin HCl 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
In Brief
A Phase 3 clinical trial evaluating Anamorelin HCl and Placebo for Cachexia and Non-Small Cell Lung Cancer. Completed, enrolled 495 participants across 46 sites in 7 countries.
Detailed Summary
The administration of Anamorelin in patients with Stage III-IV non-small cell lung cancer-cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCachexia, Non-Small Cell Lung Cancer
CountriesAustralia, Hungary, Israel, Poland, Russia, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedJul 2011
Primary CompletionNov 2013
Study CompletionFeb 2015
TodayJul 2026
First PostedJul 4, 2011
Enrollment StartJul 1, 2011
Primary CompletionNov 1, 2013
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.0 years ago
Interventions
Anamorelin HCldrug
Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
Placebodrug
Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.